Navigation Links
Jefferson is first academic medical center to offer FDA-approved BRAF mutation for melanoma patients
Date:11/8/2011

PHILADELPHIAThomas Jefferson University Hospital is the first academic medical center in the United States to offer the recently-approved U.S. Food and Drug Administration (FDA) diagnostic tool that tests melanoma patients for the BRAF mutation (which occurs in about half of all cases) and ultimately determines if they'll benefit from a new, potentially life-saving drug.

In August, the FDA approved the oral drug vemurafenib to treat patients whose melanoma cells have the BRAF V600E mutation, as determined by the companion diagnostic test, after clinical trials showed that the drug significantly extended survival in metastatic melanoma patients with the mutation.

Jefferson's clinical laboratories have officially begun utilizing the FDA-approved test to help determine melanoma patients' status and a subsequent and immediate treatment plan. According to Roche Diagnostics, its tool has improved sensitivity, accuracy and speed compared to other commonly used detection methods.

"It is very important to us at Jefferson to offer patients a personalized approach, starting with the pathology of their diseases all the way through their treatment," says Stephen C. Peiper, M.D., Peter A. Herbut Professor and Chair of the Department of Pathology, Anatomy and Cell Biology at Thomas Jefferson University.

"Melanoma is a deadly skin cancer, and this FDA-approved diagnostic tool plays a pivotal role in our approach to it. The BRAF mutation test will allow us to quickly and accurately identify patients here at the hospital who will respond positively to this new treatment," he adds.

An estimated 50 percent of patients with melanoma have this type of mutation.

The FDA approval of vemurafenib is based on results from two clinical studies in people with BRAF V600E mutation-positive, inoperable or metastatic melanoma as determined by the mutation test.

The risk of death was reduced by 56 percent for people who received vemurafenib compared to those who received chemotherapy. People who received vemurafenib also had a 74 percent reduced risk of the disease getting worse or dying compared to those who received chemotherapy. The confirmed investigator-assessed response rate (those who experienced tumor shrinkage) in people who received vemurafenib was 48.4 percent compared to 5.5 percent for those who received chemotherapy.

Vemurafenib is a BRAF inhibitor that blocks the function of the V600E-mutated BRAF protein and should be used only in people whose inoperable or metastatic melanoma carries a mutation.


'/>"/>

Contact: Steve Graff
stephen.graff@jefferson.edu
215-955-5291
Thomas Jefferson University
Source:Eurekalert

Related medicine news :

1. Thomas Jefferson University Hospital cuts Whipple procedure wound infections in half with new measures
2. Jefferson physician named an Educator of the Year by the Assocociation of Residents in Radiation Oncology
3. Thomas Jefferson University Hospital adopts new imaging agent to improve detection of bladder cancer
4. Thomas Jefferson University and hospitals tasked to find new radiation drugs
5. FDA approval of brain aneurysm device gives Jefferson neurosurgeons another life-saving tool
6. Jefferson doctors strengthen case for high-dose radiotherapy technique after radical prostatectomy
7. Kimmel Cancer Center at Jefferson breast cancer symposium features latest in research, treatment
8. Jefferson clinical trial: Can a cholesterol drug prevent colon cancer?
9. Thomas Jefferson University professor elected AAAS Fellow
10. Jefferson study determines bone marrow stromal stem cells may aid in stroke recovery
11. CancerCare names Jefferson professor Physician of the Year
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/20/2017)... ... ... to Moorwick”: the adventures of a young Scottish girl yearning to see the world. ... mother of five who used her time waiting for children to finish their extracurricular activities ... It was a way to give some meaning to the hours I waited for ...
(Date:9/20/2017)... ... 2017 , ... “Monique”: is the story of Monique, whose mother’s deteriorating ... published author, Colleen Crispi, has owned four beauty salons and written a book regarding ... estate and cooking. , “The doctor’s office was only three blocks away, and ...
(Date:9/19/2017)... ... September 19, 2017 , ... DeSola Group, a leading strategy, ... Flannery, to its strategic advisory and client development team. , In her ... clients across different industries to develop and implement market-justified strategies, modernize and transform ...
(Date:9/19/2017)... ... September 19, 2017 , ... Peter ... the President’s Malaria Initiative (PMI) Africa Indoor Residual Spraying (AIRS) Project , ... , The Innovation to Action Award, a USAID Catalyst Award, recognizes USAID ...
(Date:9/19/2017)... ... September 19, 2017 , ... CTNext , ... Innovation Awards (EIA), held this past Thursday night at The Space in Hamden. ... presented their innovative project ideas to a panel of judges for an opportunity ...
Breaking Medicine News(10 mins):
(Date:9/7/2017)... Ind. , Sept. 7, 2017  Zimmer Biomet ... in musculoskeletal healthcare, today announced that it will be ... Global Healthcare Conference at the Grand Hyatt hotel in ... 11, 2017 at 11:40 a.m. Eastern Time. ... via Zimmer Biomet,s Investor Relations website at http://investor.zimmerbiomet.com ...
(Date:9/6/2017)... , Sept. 6, 2017 NeuroRx, a clinical ... Suicidal Ideation and Behavior (ASIB), has been granted Fast Track ... sequential therapy of NRX-100 (ketamine HCl) followed by NRX-101 (D-cycloserine ... a pivotal trial of this sequential therapy targeting patients who ... 1 ...
(Date:9/5/2017)... 5, 2017  Just 18 months after its February ... to announce the appointment of three new senior people ... Dominic Jones-Phillips and James Wright ... Tammy Wynne joins ... access writers. She has over ten years, experience in ...
Breaking Medicine Technology: